Fractyl Health Faces Class Action Lawsuit Over Disputed Clinical Data

The litigation, filed by Levi & Korsinsky, LLP, covers shareholders who purchased Fractyl Health (NASDAQ: GUTS) securities between January 13, 2025, and January 29, 2026. Tensions peaked when the company reported that Revita-treated patients faced a 4.5% weight regain at the six-month mark—a stark reversal from the optimistic 2.5% loss reported just months earlier in September 2025. This discrepancy led to a cumulative stock drop of approximately 74.86% from the class-period reference price.

Central to the complaint is the integrity of the REMAIN-1 Midpoint Cohort study. Plaintiffs allege that internal operational deficiencies at one of the six study sites—specifically a lack of robust dietary counseling—compromised the trial results. While the company initially characterized its September findings as groundbreaking and statistically significant, the subsequent disclosure of weight regain and site-specific issues prompted a swift market correction, including a downward revision of Morgan Stanley’s price target from $8.00 to $2.00. Investors seeking to serve as lead plaintiff in the Southern District of New York case have until October 20, 2026, to file.